IP Library › Granted Patent US 12,251,368
Granted Patent B2
US 12,251,368 · App. 17/981,092 · Granted Mar 18, 2025

Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders

Inventor: Roger Bolsöy (Uppsala, SE)
Assignee: InTrance Medical Systems Inc.
A61K31/277A61K31/198A61K9/0014A61K9/0019A61K9/0053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,251,368
App. No.
17/981,092
Granted
Mar 18, 2025
Kind
B2
Abstract

A method of treating patients by using a pharmaceutical composition for intra-intestinal administration comprises (i) a dopamine replacement agents, (ii) a dopamine decarboxylase inhibitor (DDI), and (iii) a COMT inhibitor where the composition is continuously administered.

Claims (38)

1. A method of administering a total daily dosage of a dopamine replacement agent to a patient in need thereof wherein the patient suffers from Parkinson's disease, wherein the method comprises:

a) administering a first dosage of a pharmaceutical composition comprising the dopamine replacement agent, a dopamine decarboxylase inhibitor (DDI), and a catechol-O-methyltransferase (COMT) inhibitor, wherein the first dosage comprises 20-35% of the total daily dosage of the dopamine replacement agent; and

b) continuously administering a second dosage of the dopamine replacement agent, the DDI, and the COMT;

wherein the second dosage comprises the remainder of the total daily dosage of the dopamine replacement agent;

wherein the dopamine replacement agent is selected from the group consisting of levodopa, melevodopa, etilevodopa, derivatives thereof, and combinations thereof;

wherein the DDI is selected from the group consisting of carbidopa, benserazide, α-difluoromethyldopa [(2S)-2-amino-2-[3,4-dihydroxyphenyl)-methyl]-3,3-difluoropropanoic acid], and α-methyldopa [(S)-2-amino-3-[3,4-dihydroxyphenyl)-2-methyl-propanoic acid];

wherein the COMT inhibitor is selected from the group consisting of entacapone, tolcapone, opicapone, and combinations thereof; and

wherein the first dosage is in solid format.

2. The method of claim 1 , wherein the step of continuously administering comprises:

a) first continuously administering a first portion of the second dosage for a predetermined time; and

b) subsequently continuously administering a second portion of the second dosage, wherein the first and second portions together add up to the second dosage and wherein, for the second portion, a lower amount of the dopamine replacement agent is administered per time unit than is administered for the first portion.

3. The method of claim 1 , wherein the dopamine replacement agent, the dopamine decarboxylase inhibitor (DDI), and the catechol-O-methyltransferase (COMT) inhibitor, and optionally suitable adjuvants are contained in a single pharmaceutical composition.

4. The method of claim 1 , wherein the pharmaceutical composition comprises a first, second, and a third part, wherein the first part comprises the dopamine replacement agent, the second part comprises the dopamine decarboxylase inhibitor (DDI), and the third part comprises the catechol-O-methyltransferase (COMT) inhibitor, and wherein each part may optionally contain suitable adjuvants.

5. The method of claim 1 , wherein the pharmaceutical composition comprises:

a. a first part comprising the dopamine replacement agent and the dopamine decarboxylase inhibitor (DDI); and

b. a second part comprising the COMT inhibitor;

wherein each part optionally contains suitable adjuvants.

6. The method of claim 1 , wherein the dopamine replacement agent, the dopamine decarboxylase inhibitor (DDI), and the catechol-O-methyltransferase (COMT) inhibitor, and optionally suitable adjuvants of the first dosage are administered individually.

7. The method of claim 1 , wherein the dopamine replacement agent and the dopamine decarboxylase inhibitor (DDI) are administered at the same time, and wherein the COMT inhibitor is administered essentially at the same time as the dopamine replacement agent and the dopamine decarboxylase inhibitor (DDI).

8. The method of claim 1 , wherein the total daily dosage of dopamine replacement agent is 200 to 3500 mg.

9. The method of claim 1 , wherein the total daily dosage of dopamine replacement agent is 400 to 3000 mg.

10. The method of claim 1 , wherein the patient suffers from hyperkinetic sensitivity or has a tendency to become hyperkinetic.

11. The method of claim 1 , wherein the continuous administration is performed continuously for 24 hours.

12. The method of claim 1 , wherein the continuous administration is performed continuously for 12-18 hours.

13. The method of claim 1 , wherein the continuous administration is performed continuously for 13-17 hours or 14-16 hours.

14. The method of claim 1 , wherein the first dosage is administered in the morning.

15. The method of claim 14 , wherein the first dosage is administered between 5 am and 10 am.

16. The method of claim 1 , wherein the composition of the first dosage is an oral composition, a liquid composition, a suspension, or a gel.

17. The method of claim 16 wherein the first dosage is administered orally, intravenously, subcutaneously, intra-intestinally, or dermally.

18. The method of claim 1 , wherein the composition of the second dosage is a liquid composition, a suspension, or a gel.

19. The method of claim 18 wherein the second dosage is administered intravenously, subcutaneously, intra-intestinally, or dermally.

20. A kit comprising a first container and at least one additional container wherein the first and the at least one additional container comprises a first and a second dosage respectively of a pharmaceutical composition comprising a dopamine replacement agent, a dopamine decarboxylase inhibitor (DDI), and a catechol-O-methyltransferase (COMT) inhibitor, wherein:

a. the first dosage comprises 20-35% of the total daily dosage of the dopamine replacement agent; the second dosage comprises the remainder of the total daily dosage of the dopamine replacement agent; and

b. at least the second dosage is a liquid, a suspension or a gel,

wherein the dopamine replacement agent is selected from the group consisting of levodopa, melevodopa, etilevodopa, derivatives thereof, and combinations thereof;

wherein the DDI is selected from the group consisting of carbidopa, benserazide, a-difluoromethyldopa, and combinations thereof;

wherein the COMT inhibitor is selected from the group consisting of entacapone, tolcapone, opicapone, and combinations thereof; and wherein the first dosage is in solid format.

21. The kit according to claim 20 , wherein both the first and second dosages are liquids, suspensions or gels.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2024
From: INTRANCE INTERNATIONAL AB
To: INTRANCE MEDICAL SYSTEMS INC.
Reel/Frame 066665/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2023
From: BOLSÖY, ROGER
To: LOBSOR PHARMACEUTICALS AKTIEBOLAG
Reel/Frame 062302/0218 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2023
From: LOBSOR PHARMACEUTICALS AB
To: INTRANCE INTERNATIONAL AB
Reel/Frame 062302/0275 →
Priority Claims (1)
SE 1850327-6 · Mar 23, 2018 · national
Continuity (2)
Continuation 17040511
Related Publication 20230157989A1 · May 25, 2023
References Cited (61)
US 5635213A · Nystrom et al. · 1997 [cited by applicant]
US 6500867B1 · Virkki et al. · 2002 [cited by applicant]
US 6797732B2 · Virkki et al. · 2004 [cited by applicant]
US 8741342B2 · Goswami et al. · 2014 [cited by applicant]
US 10071069B2 · Bolsöy · 2018 [cited by examiner]
US 10555922B2 · Bolsöy · 2020 [cited by examiner]
US 10786472B2 · Bolsöy · 2020 [cited by examiner]
US 11413262B2 · Bolsöy · 2022 [cited by examiner]
US 11547689B2 · Bolsöy · 2023 [cited by examiner]
US 20060222703A1 · Politi · 2006 [cited by applicant]
US 20080118556A1 · Devane et al. · 2008 [cited by applicant]
US 20100129441A1 · Goswami et al. · 2010 [cited by applicant]
US 20130137729A1 · Rouru et al. · 2013 [cited by applicant]
US 20170231937A1 · Bolsöy · 2017 [cited by applicant]
US 20210015782A1 · Bolsoy · 2021 [cited by applicant]
CN 101132777A · 2008 [cited by applicant]
CN 101432004A · 2009 [cited by applicant]
CN 102202656A · 2011 [cited by applicant]
EP 0670713A1 · 1995 [cited by applicant]
EP 1670450A2 · 2006 [cited by applicant]
JP 2013521263A · 2013 [cited by applicant]
JP 2017527623A · 2017 [cited by applicant]
WO WO9412153A1 · 1994 [cited by applicant]
WO WO2006069030A1 · 2006 [cited by applicant]
WO WO2007138086A1 · 2007 [cited by applicant]
WO WO2008053297A2 · 2008 [cited by applicant]
WO WO2009098661A1 · 2009 [cited by applicant]
WO WO2011107653A2 · 2011 [cited by applicant]
WO WO2012066538A1 · 2012 [cited by applicant]
WO WO2012147099A1 · 2012 [cited by applicant]
WO WO2016036308A1 · 2016 [cited by applicant]
WO WO2017039525A1 · 2017 [cited by applicant]
Buongiorno, M. et al., Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry, Parkinson and Related Disorders, 31:871-876 (2015). [cited by applicant]
Brodsky, M.A. et al., Sleepiness in Parkinson's disease: a controlled study, Movement Disorders, 18:667-672 (2003). [cited by applicant]
Cabrini, S. et al., Preliminary evaluation of the DDS-PC inventory a new tool to assess impulsive-compulsive behaviors associated to dopamine replacement therapy in Parkinson's disease, Neurol Sci, 30:307-313 (2009). [cited by applicant]
Deuschl, G. et al., A randomized trial of deep-brain stimulation for Parkinson's disease, N Engl J Med, 355:896-908 (2006). [cited by applicant]
Duodopa Intestinal Gel, Datapharm, retrieved from https://www.medicines.org.uk/emc/medicine/20786, Updated on Aug. 7, 2020, 14 pages. [cited by applicant]
Esselink, R.A.J. et al., Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD—a randomized trial, Neurology, 62:201-207 (2004). [cited by applicant]
Evans, A.H. et al., Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome, Mov Disord, 19:397-405 (2004). [cited by applicant]
Fan, W.H. et al., Impulse control disorders in Parkinson's disease in a Chinese population, Neurosci Lett, 465:6-9 (2009). [cited by applicant]
Fine, J. et al., Long-Term Follow-Up of Unilateral Pallidotomy in Advanced Parkinson's Disease, The New England Journal of Medicine, 342(23):1708-1714 (2000). [cited by applicant]
Forsberg, M. et al.,Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat, J Pharmacol Exp Ther., 304(2):498-506 (2003). [cited by applicant]
Hobson, D. et al., Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease, JAMA, 287(4):455-463 (2002). [cited by applicant]
Ilias, T. et al., Individual dose-response models for levodopa infusion dose optimization, International Journal of Medical Informatics, 112:137-142 (2018). [cited by applicant]
International Search Report for PCT/SE2019/050260, received from ISA/EP, 6 pages (Jun. 27, 2019). [cited by applicant]
Katzenschlager, R. et al., Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD, Neurology, 71:474-480 (2008). [cited by applicant]
Moller, J.C. et al., Pharmacotherapy of Parkinson's disease in Germany, J Neurol, 252:926-935 (2005). [cited by applicant]
Müller, T. et al., Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease, J Neural Transm, 113:1441-1… [cited by applicant]
Nyholm, D. et al., Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial, European Journal of Neurology, 19:820-826 (2012). [cited by applicant]
Nyholm, D. et al., Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease Patients, The AAPS Journal, 15(2):31… [cited by applicant]
Nyholm, Dag, Pharmacotherapy for Parkinson's Disease—Observations and Innovations, Acta Universitatis Upsaliensis, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1236, 99 pages (2003). [cited by applicant]
Oertel, W. et al., The Sense study: An open-label, single-arm, multicentre, 6-week study evaluating the efficacy and safety of levodopa/carbidopa/entacapone (Stavelo) in Parkinson's disease patients experiencing early r… [cited by applicant]
Olanow, C. et al., Double-Blind, Double-Dummy, Randomized Study of Continuous Intrajejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease, Lancet Neurol., 13(2):141-9 (2014). [cited by applicant]
Ondo, W.G. et al., Subthalamic deep brain stimulation in patients with a previous pallidotomy, Mov Disord, 21:1252-1254 (2006). [cited by applicant]
Peralta, C.M. et al., Restless legs syndrome in Parkinson's disease, Mov Disord, 24:2076-2080 (2009). [cited by applicant]
Reimer, J. et al., Use and interpretation of on/off diaries in Parkinson's disease, J Neurol Neurosurg Psychiatry, 75:396-400 (2004). [cited by applicant]
Senek, M. et al., Levodopa-Entacapone-Carbidopa Intestinal Gel in Parkinson's Disease: A Randomized Crossover Study, Movement Disorders, 32(2):283-286 (2017). [cited by applicant]
Summary of Product Characteristics, retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/00051_1/WC500057485.pdf, 97 pages (Sep. 3, 2015). [cited by applicant]
Vingerhoets, F.J.G. et al., Subthalamic DBS replaces levodopa in Parkinson's disease—two-year follow-up, Neurology, 58:396-401 (2002). [cited by applicant]
Wenzelburger, R. et al., Force overflow and levodopa-induced dyskinesias in Parkinson's disease, Brain, 125:871-879 (2002). [cited by applicant]
Written Opinion for PCT/SE2019/050260, received from ISA/EP, 6 pages (Jun. 27, 2019). [cited by applicant]